alpn-303
alpine immune sciences
['alpn-303', 'ruby-1', '#0987', 'alpineimmune']
today, we are presenting data from alpn-303's phase 1 study (ruby-1) in a poster at 's convergence 2022 in philadelphia, pa. stop by poster #0987 in the exhibit hall from 9 - 10:30 a.m. to learn more! #acr22 
Modern therapies targeting the immune synapse. Founded 2015. (NASDAQ:ALPN)